Hellenic Osteoporosis Foundation

ΕΠΙΣΤΗΜΟΝΙΚΕΣ ΕΚΔΗΛΩΣΕΙΣ 2021-ΕΛΙΟΣ
Εμβολιασμός κατά της νόσου COVID-19 & Θεραπεία της οστεοπόρωσης
Επικαιροποίηση των Κατευθυντήριων Οδηγιών του ΕΛΙΟΣ για την αναβολική θεραπεία
Ομιλίες από τη διαδικτυακή επιστημονική συνάντηση ΕΛΙΟΣ-ΕΕΜΜΟ "Φθινοπωρινές Ημέρες Οστεοπόρωσης"

https://www.youtube.com/playlist?list=PLIyNelbH5Ev8zELelhxGgulrhs6gc l8fD
BMD After Transitioning From Denosumab to Alendronate
Approval of the marketing authorisation for Evenity (romosozumab)

Approval of the marketing authorisation for Evenity (romosozumab)
Re-examination leads to recommendation to approve

After re-examining its initial opinion, the European Medicines Agency has recommended approving the marketing authorisation for the medicine Evenity for the treatment of severe osteoporosis.
The Agency had initially refused the application on 27 June 2019 for Evenity to treat osteoporosis. After re-examination, on 17 October 2019 the Agency recommended that marketing authorisation could be granted but for a restricted indication in postmenopausal women with severe osteoporosis at high risk of fracture.
The company that applied for authorisation was UCB Pharma S.A.

Hellenic Osteoporosis Foundation

The Hellenic Osteoporosis Foundation is a non-profit Scientific Association aiming at the prevention and best treatment of Metabolic Bone Diseases by training of Greek Physicians through the publication of high quality Monographs, the organization of regular scientific meetings and the edition of the Journal “Skeletal Health”.